Grufity logoGrufity logo

CRL

222.66USD-3.54(-1.56%)Market Closed

Charles River Laboratories International Inc

Market Summary

USD222.66-3.54Market Closed
-1.56%

CRL Alerts

CRL Stock Price

RSI Chart

Valuation

Market Cap

10.9B

Price/Earnings

24.61

Price/Sales

2.96

Price/Cashflow

16.63

MarketCap/EBT

21.11

Price/Sales

Profitability

EBT Margin

13.03%

Return on Equity

16.74%

Return on Assets

5.89%

Fundamentals

Revenue

Revenue (TTM)

3.8B

Revenue Y/Y

10.4%

Revenue Q/Q

1.65%

Earnings

Earnings (TTM)

436.4M

Earnings Y/Y

-6.72%

Earnings Q/Q

-11.75%

Price Action

52 Week Range

181.36379.65
(Low)(High)

Last 7 days

-8.3%

Last 30 days

3.2%

Last 90 days

11.2%

Trailing 12 Months

-39.2%

Financial Health

Current Ratio

1.33

Debt/Equity

1.13

Debt/Cashflow

0.22

Investor Care

Shares Dilution (1Y)

0.82%

Diluted EPS (TTM)

8.49

Peers (Alternatives to Charles River Laboratories International)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
41.1B
6.7B
15.08% 3.58%
30.93
6.17
8.42% 34.14%
38.7B
14.3B
6.55% -17.13%
32.72
2.7
5.70% 54.11%
36.7B
4.7B
3.69% -38.80%
-1.9K
7.81
9.79% -558.28%
10.9B
3.8B
3.20% -39.16%
24.61
2.96
10.37% 10.04%
MID-CAP
6.9B
1.4B
-0.53% -1.06%
30.49
5.03
25.69% 24.11%
5.2B
5.4B
-28.76% -64.60%
18.72
0.96
8.57% 14.42%
3.8B
243.2M
-1.96% -51.31%
-24.67
15.19
75.89% -25.00%
SMALL-CAP
955.6M
3.3M
2.29% -33.20%
-21.05
291.16
-26.92% -26.56%
942.2M
496.8M
58.31% -64.07%
-6.42
1.93
2.51% -434.48%
728.9M
60.3M
-14.86% -77.13%
-1.39
13.26
17.51% -38.87%
372.0M
132.7M
-1.39% -83.46%
-19.64
2.76
31.03% -107.73%
335.1M
75.9M
15.24% -52.63%
-3.66
4.15
9.61% 123.40%
122.6M
69.0M
6.30% -78.45%
-1.31
1.6
-18.80% -75.52%

Financials for Charles River Laboratories International

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue2.5%3,7813,6883,6303,5403,426
  S&GA Expenses6.1%610574614620619
Earnings Before Taxes-481
Net Income-1.6%436443422391397
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-1.9%7,3837,5297,0757,0247,058
  Current Assets1.6%1,4151,3931,3331,2741,379
    Cash Equivalents-3.3%194200242241213
  Inventory1.9%262257221199182
  Net PPE-1,291----
  Goodwill-2.9%2,7762,8602,6962,7122,736
Liabilities-2.6%4,7114,8364,4044,4324,594
  Current Liabilities-3.2%1,0141,0489941,033984
  Long Term Debt-2.0%2,9372,9972,6762,6642,893
    LT Debt, Current-100.0%-0000
Shareholder's Equity-0.8%2,6272,6482,6102,5352,427
  Retained Earnings8.2%1,2801,1831,074981879
  Additional Paid-In Capital1.1%1,7811,7611,7451,7181,720
Accumulated Depreciation-1,103----
Shares Outstanding0.0%5151515050
Minority Interest12.7%65545
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-6.4%614656693761670
  Share Based Compensation0.0%7171737168
Cashflow From Investing29.0%-643.00-905.86-1,397.94-1,437.93-1,535.66
Cashflow From Financing-105.7%-12.41218465673832
  Buy Backs-0.3%3939394141

Risks

What is the probability of a big loss on CRL?

40%


Probability that Charles River Laboratories International stock will be more than 20% underwater in next one year

35.4%


Probability that Charles River Laboratories International stock will be more than 30% underwater in next one year.

33.1%


Probability that Charles River Laboratories International stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CRL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Charles River Laboratories International was unfortunately bought at previous high price.

Returns

Cumulative Returns on CRL

19.0%


10-Year Cumulative Returns

16.4%


7-Year Cumulative Returns

16.4%


5-Year Cumulative Returns

15.7%


3-Year Cumulative Returns

What are the long-term rolling returns for CRL?

FIve years rolling returns for Charles River Laboratories International.

Which funds bought or sold CRL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
SOLD OFF
-100
-243,000
-
-%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-54.98
-78,443
57,000
0.04%
2022-11-23
Toroso Investments, LLC
ADDED
4.78
-8,000
225,000
0.01%
2022-11-22
CVA Family Office, LLC
ADDED
157.89
11,000
19,000
-%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
8.02
-2,000
272,000
0.01%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
906,000
906,000
0.01%
2022-11-21
Parallax Volatility Advisers, L.P.
NEW
-
110,000
110,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
ADDED
1.15
-1,244,000
16,604,000
0.03%
2022-11-21
FourThought Financial, LLC
ADDED
21.33
5,000
50,000
0.01%
2022-11-18
Future Fund LLC
REDUCED
-3.69
-36,000
277,000
0.56%

1–10 of 45

Latest Funds Activity

Are funds buying CRL calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own CRL

Charles River Laboratories International News

MarketWatch

Illumina Inc. stock underperforms Friday when compared to competitors.2 days ago

CRL Fair Value

Recent SEC filings of Charles River Laboratories International

View All Filings
Date Filed Form Type Document
Nov 30, 2022
8-K
Current Report
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 07, 2022
4
Insider Trading
Nov 02, 2022
8-K
Current Report
Nov 02, 2022
10-Q
Quarterly Report
Nov 01, 2022
3
Insider Trading

Latest Insider Trading transactions for CRL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-16
Knell Michael Gunnar
SOLD
-212,544
248.59
-855
CSVP&Chief Accounting Officer
2022-11-16
Knell Michael Gunnar
ACQUIRED
93,485.7
109.34
855
CSVP&Chief Accounting Officer
2022-11-15
Parisotto Shannon M
ACQUIRED
249,186
109.34
2,279
CEVP, Disc & Safety Assessment
2022-11-15
Parisotto Shannon M
SOLD
-569,522
249.9
-2,279
CEVP, Disc & Safety Assessment
2022-11-04
LaPlume Joseph W
SOLD
-115,536
216.36
-534
EVP, Corp Strategy & Develop
2022-08-05
LaPlume Joseph W
SOLD
-45,226.8
226.134
-200
EVP, Corp Strategy & Develop
2022-07-06
LaPlume Joseph W
GIFTED
-
-
-195
EVP, Corp Strategy & Develop
2022-05-29
Creamer Victoria L
SOLD (Taxes)
-46,437.9
244.41
-190
EVP & Chief People Officer
2022-05-29
Knell Michael Gunnar
SOLD (Taxes)
-13,198.1
244.41
-54
CSVP&Chief Accounting Officer
2022-05-29
Barbo William D
SOLD (Taxes)
-49,370.8
244.41
-202
Corporate Executive VP & CCO

1–10 of 50

James C. Foster
20000
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

CRL Income Statement

2022-09-24
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Sep. 24, 2022
Sep. 25, 2021
Total revenue$ 989,157$ 895,937$ 2,876,217$ 2,635,110
Costs and expenses:    
Selling, general and administrative183,714148,573465,458475,807
Amortization of intangible assets35,53332,852111,14494,664
Operating income150,976155,802487,165417,055
Other income (expense):    
Interest income122137437343
Interest expense(11,375)(16,455)(24,512)(62,364)
Other expense, net(16,616)(16,214)(85,024)(37,966)
Income before income taxes123,107123,270378,066317,068
Provision for income taxes25,49518,11174,56458,058
Net income97,612105,159303,502259,010
Less: Net income attributable to noncontrolling interests1,1391,7334,6865,606
Net income attributable to common shareholders$ 96,473$ 103,426$ 298,816$ 253,404
Earnings per common share    
Basic (in dollars per share)$ 1.90$ 2.05$ 5.88$ 5.04
Diluted (in dollars per share)$ 1.88$ 2.01$ 5.83$ 4.93
Weighted-average number of common shares outstanding:    
Basic (in shares)50,87050,42550,77850,234
Diluted (in shares)51,28351,55851,28551,360
Service    
Total revenue$ 812,894$ 703,859$ 2,316,206$ 2,045,760
Costs and expenses:    
Cost of services provided and products sold (excluding amortization of intangible assets)530,706468,6591,540,1931,369,396
Product    
Total revenue176,263192,078560,011589,350
Costs and expenses:    
Cost of services provided and products sold (excluding amortization of intangible assets)$ 88,228$ 90,051$ 272,257$ 278,188

CRL Balance Sheet

2022-09-24
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Sep. 24, 2022
Dec. 25, 2021
Current assets:  
Cash and cash equivalents$ 193,701$ 241,214
Trade receivables and contract assets, net of allowances for credit losses of $9,827 and $7,180, respectively770,776642,881
Inventories261,522199,146
Prepaid assets92,26693,543
Other current assets97,08797,311
Total current assets1,415,3521,274,095
Property, plant and equipment, net1,380,5681,291,068
Operating lease right-of-use assets, net373,410292,941
Goodwill2,776,0052,711,881
Client relationships and other intangible assets, net968,0201,061,192
Deferred tax assets39,72140,226
Other assets429,693352,889
Total assets7,382,7697,024,292
Current liabilities:  
Current portion of long-term debt and finance leases2,0792,795
Accounts payable181,629198,130
Accrued compensation200,365246,119
Deferred revenue251,473219,703
Accrued liabilities196,754228,797
Other current liabilities181,894137,641
Total current liabilities1,014,1941,033,185
Long-term debt, net and finance leases2,937,0562,663,564
Operating lease right-of-use liabilities368,851252,972
Deferred tax liabilities196,014239,720
Other long-term liabilities194,710242,859
Total liabilities4,710,8254,432,300
Commitments and contingencies (Notes 2, 9, 11 and 13)
Redeemable noncontrolling interests39,20653,010
Equity:  
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding00
Common stock, $0.01 par value; 120,000 shares authorized; 51,006 shares issued and 50,877 shares outstanding as of September 24, 2022, and 50,480 shares issued and outstanding as of December 25, 2021510505
Additional paid-in capital1,780,8761,718,304
Retained earnings1,279,567980,751
Treasury stock, at cost, 129 and 0 shares, as of September 24, 2022 and December 25, 2021, respectively(38,492)0
Accumulated other comprehensive loss(395,608)(164,740)
Total equity attributable to common shareholders2,626,8532,534,820
Noncontrolling interest5,8854,162
Total equity2,632,7382,538,982
Total liabilities, redeemable noncontrolling interests and equity7,382,7697,024,292
Client relationships, net  
Current assets:  
Client relationships and other intangible assets, net909,899981,398
Other intangible assets, net  
Current assets:  
Client relationships and other intangible assets, net$ 58,121$ 79,794